Company intelligence / Profile preview
Hangzhou Adcoris Biopharmaceuticals
Hangzhou, Zhejiang, Chinaadcoris.com.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The company’s lead asset ACR246 is a next-generation antibody-drug conjugate targeting the oncofetal antigen "5T4" for solid tumors. It has demonstrated substantial anti-tumor activity and safety in preclinical models and entered first-in-human trials in early Q4 of 2024. Additional pipeline assets are at various stages from preclinical to IND-enabling.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADC)Dual payload ADCsBispecific ADCsAntibody immunomodulator conjugates (AIC/AXC)Antibody-PROTAC conjugates (APC)Antibody oligonucleotide conjugates (AOC)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Lunan Pharmaceutical Group — strategic collaboration agreement for joint development of one to two antibody-drug conjugate products.
Beyond the preview
Go deeper on Hangzhou Adcoris Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hangzhou Adcoris Biopharmaceuticals.